

## ASX Release

### Appendix 4C – Q4 2018 Quarterly Cash Flow Report

31 January 2019 – Sydney, Australia – Oneview Healthcare PLC (ASX:ONE) today released its Appendix 4C – Quarterly Cashflow report for the period ending 31<sup>st</sup> December 2018.

#### Financial Highlights

Operating cash net outflows for the quarter were €2.53 million which included:

- Receipts from customers of €3.57 million (vs. guidance in previous 4C of €2.5 - €3.0m) +38% from prior quarter and +38% from the corresponding quarter of the previous year.
- Payments for staff costs in the quarter amounted to €4.14 million, -9% from the prior quarter and -18% from the corresponding quarter of the previous year.
- Payments for admin and corporate costs in the quarter amounted to €1.14 million, -13% from the prior quarter and -24% from the corresponding quarter of the previous year.
- Direct costs incurred for hardware and implementation amounted to €0.68 million (€1.71 million for the prior quarter).
- Cash balances as at 31<sup>st</sup> December 2018 amounted to €9.33 million.

The company's business model is predicated on a recurring revenue model. Oneview continues to adopt a pro-active approach to its cost base in response to changing trading conditions.

#### Operational Highlights

During the period, the company achieved the following operational highlights:

- Sydney Children's Hospital Network signed an extension agreement to implement the Oneview platform across 203 beds at their Randwick facility, commencing in January 2019.
- An additional 67 beds went live at Mediclinic's new Parkview Hospital in Dubai.
- Oneview Healthcare went live in Bumrungrad International Hospital's flagship hospital across 431 beds at Sukhumvit 3 in Bangkok, Thailand.
- The company migrated 351 beds at BJC Healthcare in St. Louis from its legacy Gen 2 product to its new Android Gen 3 product.
- The company commenced deployment of hardware and entertainment services for the Mater project in Brisbane, Australia.

A strategic review to optimise capital allocation and governance to sustainably deliver shareholder returns was completed during the period. As a result of this review:


- The existing product portfolio has been reduced from four products (Inpatient, Senior Living, Pathways and Connect) to two products only (Inpatient and Senior Living);
- New feature development on Connect has been suspended for at least the next 12 months; and
- The company is seeking a strategic partner to fund the continued development of the Pathways product with Oxford.

Simplification of the portfolio will allow Oneview to focus resources on accelerated innovation and market share for the Inpatient product (currently 90% of revenues) and on delivering the Senior Living Product for our first enterprise customers. It also reduces complexity and is expected to result in targeted 2019 operating cost savings (including the impact of previously announced leadership reorganisation) of approximately €4.0 million vs. prior estimates. Consistent with this approach to streamline operations, the Board of Directors of Oneview Healthcare has reviewed its corporate governance and has reduced the number of executive Directors appointed to the Board from three to two; and reduced the number of non-executive Directors from six to three, commensurate with listed Boards of similar sized businesses on the ASX.

Full time headcount at the end of December was 134 (September 2018: 142) down from a peak of 185.

### Impact of the Strategic Review

The impact of the previously announced changes is best illustrated in the following chart showing cash-flow trends for the past 8 quarters. You will note the substantial improvement in cash-flow over the past 2 years but especially in the last quarter, where customer receipts grew by 38%. You will also note our quarterly overheads are expected to be 36% lower than they were in Q2 2017.



### About Oneview Healthcare

Oneview provides interactive healthcare technologies for patients, families and caregivers. Oneview's technology weaves a facility's existing disparate systems into a single seamless platform, allowing healthcare facilities to engage patients in meaningful ways, improve communication, and streamline clinical workflows. Patients enjoy the comfort and convenience of information, education, entertainment and environmental controls at the bedside, while facilities enjoy better health outcomes and patient satisfaction.

Enquiries: James Fitter, CEO or John Kelly, CFO

Oneview Healthcare

Website: [www.oneviewhealthcare.com](http://www.oneviewhealthcare.com)

## Appendix 4C

## Quarterly report for entities subject to Listing Rule 4.7B

Introduced 31/03/00. Amended 30/09/01, 24/10/05, 17/12/10, 01/09/16

## Name of entity

Oneview Healthcare PLC

## ABN

610 611 768

## Quarter ended ("current quarter")

31<sup>st</sup> December 2018

Consolidated statement of cash flows	Current quarter €'000	Year to date (12 months) €'000
<b>1. Cash flows from operating activities</b>		
1.1 Receipts from customers	3,572	9,982
1.2 Payments for		
(a) research and development	-	-
(b) product manufacturing and operating costs	(683)	(4,166)
(c) advertising and marketing	(89)	(620)
(d) leased assets	-	-
(e) staff costs	(4,144)	(17,859)
(f) administration and corporate costs	(1,143)	(4,819)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	-	-
1.5 Interest and other costs of finance paid	-	-
1.6 Income taxes (paid) / refunded	262	312
1.7 Government grants and tax incentives	-	-
1.8 Other (provide details if material) – incl. general working capital movements.	(306)	(1,314)
<b>1.9 Net cash from / (used in) operating activities</b>	<b>(2,531)</b>	<b>(18,484)</b>

Consolidated statement of cash flows		Current quarter €'000	Year to date (12 months) €'000
<b>2.</b>	<b>Cash flows from investing activities</b>		
2.1	Payments to acquire:		
	(a) property, plant and equipment	(120)	(572)
	(b) businesses (see item 10)	-	-
	(c) investments	-	-
	(d) intellectual property	(172)	(172)
	(e) other non-current assets	-	-
2.2	Proceeds from disposal of:		
	(a) property, plant and equipment	-	-
	(b) businesses (see item 10)	-	-
	(c) investments	-	-
	(d) intellectual property	-	-
	(e) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
<b>2.6</b>	<b>Net cash from / (used in) investing activities</b>	<b>(292)</b>	<b>(744)</b>

<b>3.</b>	<b>Cash flows from financing activities</b>		
3.1	Proceeds from issue of shares	-	-
3.2	Proceeds from issue of convertible notes	-	-
3.3	Proceeds from exercise of share options	-	3
3.4	Transaction costs related to issue of shares, convertible notes or options	-	-
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	-	-
<b>3.10</b>	<b>Net cash from / (used in) financing activities</b>	<b>-</b>	<b>3</b>

Consolidated statement of cash flows		Current quarter €'000	Year to date (12 months) €'000
<b>4.</b>	<b>Net increase / (decrease) in cash and cash equivalents for the period</b>		
4.1	Cash and cash equivalents at beginning of quarter/year to date	12,151	28,611
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(2,531)	(18,484)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(292)	(744)
4.4	Net cash from / (used in) financing activities (item 3.10 above)	-	3
4.5	Effect of movement in exchange rates on cash held	3	(55)
<b>4.6</b>	<b>Cash and cash equivalents at end of quarter</b>	<b>9,331</b>	<b>9,331</b>

<b>5.</b>	<b>Reconciliation of cash and cash equivalents</b> at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter €'000	Previous quarter €'000
5.1	Bank balances	9,331	12,151
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
<b>5.5</b>	<b>Cash and cash equivalents at end of quarter (should equal item 4.6 above)</b>	<b>9,331</b>	<b>12,151</b>

6.	Payments to directors of the entity and their associates	Current quarter €'000
6.1	Aggregate amount of payments to these parties included in item 1.2	284
6.2	Aggregate amount of cash flow from loans to these parties included in item 2.3	-
6.3	Include below any explanation necessary to understand the transactions included in items 6.1 and 6.2	

7. Payments to related entities of the entity and their associates	Current quarter €'000
7.1 Aggregate amount of payments to these parties included in item 1.2	-
7.2 Aggregate amount of cash flow from loans to these parties included in item 2.3	-
7.3 Include below any explanation necessary to understand the transactions included in items 7.1 and 7.2	

8. Financing facilities available <i>Add notes as necessary for an understanding of the position</i>	Total facility amount at quarter end €'000	Amount drawn at quarter end €'000
8.1 Loan facilities	-	-
8.2 Credit standby arrangements	-	-
8.3 Other (please specify)	-	-
8.4 Include below a description of each facility above, including the lender, interest rate and whether it is secured or unsecured. If any additional facilities have been entered into or are proposed to be entered into after quarter end, include details of those facilities as well.		

9. Estimated cash outflows for next quarter	€'000
9.1 Research and development	-
9.2 Product manufacturing and operating costs	(415)
9.3 Advertising and marketing	(58)
9.4 Leased assets	-
9.5 Staff costs	(4,102)
9.6 Administration and corporate costs	(731)
9.7 Other (provide details if material)	-
<b>9.8 Total estimated cash outflows</b>	<b>(5,306)</b>

10.	Acquisitions and disposals of business entities (items 2.1(b) and 2.2(b) above)	Acquisitions	Disposals
10.1	Name of entity	-	-
10.2	Place of incorporation or registration	-	-
10.3	Consideration for acquisition or disposal	-	-
10.4	Total net assets	-	-
10.5	Nature of business	-	-

### Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.



Sign here: .....  
(Director)

Date: 31 January 2019

Print name: James Fitter

### Notes

1. The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity that wishes to disclose additional information is encouraged to do so, in a note or notes included in or attached to this report.
2. If this quarterly report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.